Literature DB >> 8371328

Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.

S G Adams1, E J Hunt, D A Charles, A E Lang.   

Abstract

The present study compared the effects of unilateral and bilateral thyroarytenoid injections of botulinum toxin (botox) for the treatment of adductor spasmodic dysphonia. Using electromyographic guidance, 15 patients received unilateral botox injections of 15 units each and 11 patients received bilateral injections of 2.5 units in each site. Acoustic recordings of the patient's voice were made prior to injection and at two- and six-week intervals after injection. Both the unilateral and bilateral botox injections were associated with significant improvements in spasmodic dysphonia. This was determined by the acoustic measures of vocal shimmer and the number of voice breaks per second and by the perceptual measures of voice spasm severity. Both types of injections were also associated with a significant increase in vocal breathiness at two weeks post-injection. In addition, a number of acoustic measures including maximum phonation time, vocal jitter, and the number of voice breaks/second indicated that unilateral botox injections may provide both superior and longer lasting benefits than bilateral botox injections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8371328

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  7 in total

1.  The consequences of spasmodic dysphonia on communication-related quality of life: a qualitative study of the insider's experiences.

Authors:  Carolyn R Baylor; Kathryn M Yorkston; Tanya L Eadie
Journal:  J Commun Disord       Date:  2005 Sep-Oct       Impact factor: 2.288

2.  The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences.

Authors:  Carolyn R Baylor; Kathryn M Yorkston; Tanya L Eadie; Nicole C Maronian
Journal:  J Voice       Date:  2006-03-29       Impact factor: 2.009

3.  Spasmodic dysphonia as a presenting symptom of spinocerebellar ataxia type 12.

Authors:  Jessica Rossi; Francesco Cavallieri; Giada Giovannini; Carla Budriesi; Annalisa Gessani; Miryam Carecchio; Daniela Di Bella; Elisa Sarto; Jessica Mandrioli; Sara Contardi; Stefano Meletti
Journal:  Neurogenetics       Date:  2019-06-13       Impact factor: 2.660

4.  Optimizing Botox regimens in patients with adductor spasmodic dysphonia and essential tremor of voice: A 31-year experience.

Authors:  Amy Stone; Maria E Powell; Kaitlyn Hamers; K Charles Fletcher; David O Francis; Mark S Courey; James L Netterville; C Gaelyn Garrett
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-19

Review 5.  Chemodenervation of the Larynx.

Authors:  Rachel Kaye; Andrew Blitzer
Journal:  Toxins (Basel)       Date:  2017-11-02       Impact factor: 4.546

6.  Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.

Authors:  Tahwinder Upile; Behrad Elmiyeh; Waseem Jerjes; Vyas Prasad; Panagiotis Kafas; Jesuloba Abiola; Bryan Youl; Ruth Epstein; Colin Hopper; Holger Sudhoff; John Rubin
Journal:  Head Face Med       Date:  2009-10-24       Impact factor: 2.151

Review 7.  Botulinum toxin injections for the treatment of spasmodic dysphonia.

Authors:  C C W Watts; R Whurr; C Nye
Journal:  Cochrane Database Syst Rev       Date:  2004
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.